Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia

Abstract

BACKGROUND Maintenance therapy with imatinib during the post-transplant period has been used for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL); however, its efficacy has not been demonstrated. A study was designed to investigate the safety of imatinib and its efficacy in preventing hematological relapse and improving… (More)
DOI: 10.1186/1756-8722-5-29

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Chen2012AdministrationOI, title={Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia}, author={Huan Chen and Kai-yan Liu and Lan-Ping Xu and Dai-hong Liu and Yu-hong Chen and Xiang-Yu Zhao and Wei Han and Xiaohui Zhang and Yu Wang and Yuan-yuan Zhang and Ya-zhen Qin and Yan-rong Liu and Xiao-Jun Huang}, booktitle={Journal of hematology & oncology}, year={2012} }